Clik here to view.
How patients and others react to prostate cancer diagnosis and treatment
According to a media release issued earlier today by ZERO — The End of Prostate Cancer in conjunction with Ferring Pharmaceuticals Inc., “Prostate cancer impacts sex lives more than any other aspect of...
View ArticleClik here to view.
NCI launches “exceptional responders” initiative
It is well understood that some patients exhibit exceptionally good responses to investigational and to standard forms of treatment for cancer — well beyond the responses exhibited by the majority of...
View ArticleClik here to view.
More on the costs of new cancer treatments
As some of our regular readers will be aware, a new form of cancer therapy known as “chimeric antigen receptor T-cell” therapy (often known as CART or CAR-T) is currently in advanced stages of...
View ArticleClik here to view.
Serum lipid levels and post-surgical risk for prostate cancer recurrence
According to an article published today in Cancer Epidemiology, Biomarkers and Prevention, men with dyslipidemia (an abnormal lipid profile) and elevated total cholesterol levels who have surgery for...
View ArticleClik here to view.
Current options for treatment of radiorecurrent, localized prostate cancer
For men who choose to have radiotherapy (external photon beam, external proton beam, or brachytherapy of some type) as first-line therapy for localized prostate cancer, a major issue is, “What if the...
View ArticleClik here to view.
Do [11C]choline PET/CT scan data change clinical decision-making?
The practical value of any type of diagnostic and prognostic technology can only really be assessed in the context of whether the data generated by that technology change the way that physicians treat...
View ArticleClik here to view.
Introduction of a proposed National Prostate Cancer Council Act
So, according to a communication to its members from the American Urological Association (AUA), U.S. Senators Barbara Boxer (D, CA) and Jeff Sessions (R, AL) have just introduced S. 2813, the National...
View ArticleClik here to view.
Second-line therapy for progressive, high-risk prostate cancer: time for a...
Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a...
View ArticleClik here to view.
Poorer outcomes for BRCA1/2 carriers after standard treatment
It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard...
View ArticleClik here to view.
Bill Manning’s blog: Part VII
Here is the seventh of Bill’s blog posts. He, and we, hope it will be helpful to all those battling late stage prostate cancer as he takes advantage of some of the new drugs that have come to market...
View ArticleClik here to view.
New US national prostate cancer data classified by NCCN risk category
Prior to 2013, when the National Cancer Institute released accumulated, de-identified, prostate cancer-specific patient data from the national SEER cancer registry, those data only included the...
View ArticleClik here to view.
Factors in the sequencing of late-stage prostate cancer treatments
A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer...
View ArticleClik here to view.
The Prostate Health Cocktail in management of biochemically recurrent...
A newly published paper by some highly regarded researchers provides data from a small, Phase II trial of Prostate Health Cocktail (PHC) — an “over-the-counter” combination herbal supplement — in the...
View ArticleClik here to view.
Expansion of health insurance and prostate cancer outcomes
An article originally published in Prostate Cancer and Prostatic Diseases, earlier this year, predicts that expansion of insurance coverage here in the USA will have major impact on prostate cancer...
View ArticleClik here to view.
Guidelines and the current treatment of mCRPC
The December 1 issue of The ASCO Post contains two articles that will be of interest to many patients with progressive disease and their family members. The first article, by Matthew Stenger, is a...
View ArticleClik here to view.
Data from large Swedish study supports exercise after first-line therapy
According to a media release issued by the American Association for Cancer Research (AACR) new data from a large Swedish study show lower overall and prostate cancer-specific mortality in prostate...
View ArticleClik here to view.
Treatment regret among men with recurrent prostate cancer
The issue of treatment regret comes up regularly among men after first-line treatment for localized prostate cancer, but has been less commonly addressed among men with recurrent disease...
View ArticleClik here to view.
Can invasive procedures spread prostate cancer?
Prostate cancer is seldom spread by invasive procedures such as biopsies, prostatectomy, TURP, LDR brachytherapy, HDR brachytherapy, or insertion of fiducials for image-guided radiotherapy. We know...
View ArticleClik here to view.
Ageism in prostate cancer treatment
We’ve all heard the age-related treatment recommendations of doctors. Comments like: “I don’t recommend surgery for patients over 70.” “Active surveillance is only for older men.” “Radiation is only...
View ArticleClik here to view.
Stem cells from fat and the management of post-surgical incontinence
Credit where credit is due. … Our friends at The Daily Mail in England have actually come up with some prostate cancer-related news worth passing on! According to this article in The Daily News on...
View Article